A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Sponsored by Alentis Therapeutics AG
About this study
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.
This Study has a Phase I ALE.P02 monotherapy dose escalation and recommended dose for expansion (RDE) study and a Phase II study of ALE.P02 as monotherapy at RP2D in adult patients with selected advanced or metastatic Claudin-1 positive (CLDN1+) cancers.
Where this study is enrolling (2)
- I'm interested
Mayo Foundation for Medical Education and Research - Mayo Cl
Scottsdale, Arizona
- Call 773-702-1234
The University of Chicago Medical Center - Oncology
Chicago, Illinois
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
Who can participate
Inclusion criteria
- ✓Have disease and treatment history as: Have histologically or cytologically confirmed advanced locally recurrent and inoperable or metastatic SqNSCLC, HNSCC (nasopharyngeal cancer included), ESCC or CSCC.
- ✓Phase I Dose Escalation: Have received at least one systemic standard of care regimen and being refractory or intolerant to the treatment.
- ✓Phase I RDE and Phase II: Have received no more than 2 lines of systemic standard of care regimen and being refractory or intolerant to the treatment.
- ✓Have provided tissue for CLDN1 analysis in a central laboratory.
- ✓Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group Performance Scale.
- ✓Demonstrate adequate bone marrow and organ function.
- ✓Patients must have recovered from all toxicities led by prior treatment.
- ✓Have measurable disease based on RECIST 1.1 as determined by the site.
Exclusion criteria
- ✕Diagnosed with cancers of predominantly non-squamous histology (eg, adenosquamous carcinoma) or adenocarcinoma.
- ✕Has received antineoplastic therapies prior to study intervention within specified time frame.
- ✕Has rapidly progressing disease (eg, tumor bleeding, uncontrolled tumor pain).
- ✕Patients with uncontrolled diabetes.
- ✕Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- ✕Has clinically significant gastrointestinal bleeding and has an active infection requiring systemic treatment and has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the clinical study, interfere with the patient's participation for the full duration of the clinical study, or is not in the best interest of the patient to participate.
- ✕Concomitant use of drugs that are known to prolong or shorten QT and/or have known risk of Torsades de Pointes.
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.